Principles of Antimicrobial Selection

Initial Assessment & Pathogen ID - Know Your Enemy

• Clinical Clues: History, symptoms, infection site. Host: age, immunosuppression (e.g., HIV, steroids), comorbidities, allergies.
• Specimen First: Correct site, aseptic technique, adequate volume.

  ⭐ Blood cultures should ideally be drawn before initiating antimicrobial therapy to maximize diagnostic yield, especially in suspected sepsis.

• Lab Diagnosis:
  • Microscopy:
    • Gram stain: Key initial differentiator (Gram +ve vs -ve, morphology).
    • 
    • ZN stain (AFB), KOH (fungi).
  • Culture & Sensitivity (C&S): Identifies pathogen, MIC.
  • Rapid Tests: PCR, antigen detection.
  • Biomarkers: Procalcitonin (PCT), CRP.
• Specimen Testing Priority:

📌 Mnemonic (ID Steps): Specimen, Stain, Culture, Sensitivity (SSCS - "Sure Shot Clinical Success").

Host Factors - Patient Matters Most

• Allergies: Document & avoid; paramount.
• Age:
  • Neonates: Chloramphenicol (Grey Baby), Sulfonamides (kernicterus) contraindicated.
  • Elderly: Adjust for ↓renal/hepatic function.
• Organ Dysfunction:
  • Renal: Dose adjust aminoglycosides, vancomycin, many β-lactams.

    ⭐ Aminoglycosides require careful dose monitoring and adjustment in patients with renal impairment due to their nephrotoxicity and primary renal excretion.

  • Hepatic: Caution: macrolides, metronidazole.
• Pregnancy/Lactation: Many C/I. 📌 e.g., Tetracyclines, Fluoroquinolones, Aminoglycosides.
• Site of Infection: Ensure penetration (CSF, bone, prostate).
• Immune Status: Compromised may need bactericidal/broader agents.
• Genetic Factors: G6PD deficiency (sulfonamides, nitrofurantoin → hemolysis).

Drug Properties & Spectrum - Weapon of Choice

• Pharmacokinetic/Pharmacodynamic (PK/PD) Parameters: Optimize dosing strategy.

  • Concentration-dependent: Maximize peak $C_{max}/MIC$ (e.g., Aminoglycosides, Fluoroquinolones).
  • Time-dependent: Maximize duration $T>MIC$ (e.g., Beta-lactams, Vancomycin).
  • AUC/MIC dependent: Maximize exposure $AUC_{24}/MIC$ (e.g., Azithromycin, Linezolid, Vancomycin for MRSA).

• Spectrum of Activity:

  • Narrow: Targets few species (e.g., Penicillin G for Gram-positive cocci).
  • Extended: Broader coverage than original narrow spectrum (e.g., Piperacillin).
  • Broad: Active vs Gram-positive & Gram-negative (e.g., Imipenem, Tetracyclines). ⚠️ Risk: Superinfections, resistance.

• Bactericidal vs. Bacteriostatic:

  • Cidal: Kills bacteria. Preferred for severe infections, immunocompromised. 📌 VFPACM (Vancomycin, Fluoroquinolones, Penicillins, Aminoglycosides, Cephalosporins, Metronidazole).
  • Static: Inhibits growth. Host immunity crucial. 📌 ECSTaTiC (Erythromycin, Clindamycin, Sulfonamides, Tetracyclines, Trimethoprim, Chloramphenicol).

⭐ Beta-lactam antibiotics exhibit time-dependent killing; their efficacy is optimized by maintaining drug concentrations above the MIC for an extended duration of the dosing interval.

Therapeutic Strategies & Stewardship - Smart Combat Plan

• Empirical Therapy: Initial broad-spectrum treatment for suspected severe infections before C&S.
• Definitive Therapy: Targeted narrow-spectrum therapy guided by C&S results.
• Prophylactic Therapy: Prevent infection (e.g., pre-surgery, immunocompromised).
• Combination Therapy: Use of >1 agent. 📌 PASTE for indications:
  • Polymicrobial infections.
  • Antibiotic synergism (e.g., β-lactam + aminoglycoside).
  • Severe infections (broad empirical cover).
  • Toxicity reduction (lower individual drug doses).
  • Emergence of resistance prevention (e.g., TB, HIV).
• Antimicrobial Stewardship (AMS):
  • Goal: Optimize use, ↓resistance, improve patient outcomes.
  • Key principles: The 5 Ds (Drug, Dose, De-escalation, Duration, Diagnosis).

⭐ De-escalation therapy, guiding by culture and sensitivity results to switch from broad-spectrum to narrower-spectrum agents, is a cornerstone of antimicrobial stewardship to reduce resistance.

High‑Yield Points - ⚡ Biggest Takeaways

• Empirical therapy: Based on clinical presentation, likely pathogens, and local antibiograms; start promptly.
• Definitive therapy: Guided by Culture & Sensitivity (C&S) results for optimal pathogen targeting.
• Bactericidal over bacteriostatic for immunocompromised or severe infections (meningitis, endocarditis).
• Key host factors (age, pregnancy, organ dysfunction, allergies, site of infection) critically influence drug choice.
• Combination therapy: Employed for synergism, to prevent resistance, or for polymicrobial/empirical coverage.
• PK/PD parameters (T>MIC, AUC/MIC) guide optimal dosing and prevent resistance.
• Prophylaxis: Prevents infection in high-risk situations (e.g., surgery, exposures).